1,124
Views
14
CrossRef citations to date
0
Altmetric
Review

Management of Charcot–Marie–Tooth disease: improving long-term care with a multidisciplinary approach

, &
Pages 7-19 | Published online: 19 Jan 2016

References

  • DyckPJInherited neuronal degeneration and atrophy affecting peripheral motor, sensory and autonomic neuronsDyckPJThomasPKLambertEHPeripheral NeuropathyPhiladelphiaWB Saunders1975825867
  • DyckPJLambertEHLower motor and primary sensory neuron diseases with peroneal muscular atrophy. II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerationsArch Neurol19681866036184297451
  • NicholsonGMyersSIntermediate forms of Charcot-Marie-Tooth neuropathy: a reviewNeuromolecular Med200681–212313016775371
  • BirdTDCharcot-Marie-Tooth Hereditary Neuropathy OverviewPagonRAAdamMPArdingerHHGeneReviewsSeattle (WA)University of Washington, Seattle1993–2015
  • ZuchnerSDe JonghePJordanovaAAxonal neuropathy with optic atrophy is caused by mutations in mitofusin 2Ann Neurol200659227628116437557
  • VerhoevenKClaeysKGZuchnerSMFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2Brain2006129Pt 82093210216714318
  • CombarrosOCallejaJPoloJMBercianoJPrevalence of hereditary motor and sensory neuropathy in CantabriaActa Neurol Scand19877519123472423
  • KuriharaSAdachiYWadaKAwakiEHaradaHNakashimaKAn epidemiological genetic study of Charcot-Marie-Tooth disease in Western JapanNeuroepidemiology200221524625012207153
  • SkreHGenetic and clinical aspects of Charcot-Marie-Tooth’s diseaseClin Genet197462981184430158
  • WiszniewskiWSzigetiKLupskiJRChapter 126 – Hereditary Motor and Sensory NeuropathiesRimoinDLPyeritzREKorfBEmery and Rimoin’s Principles and Practice of Medical GeneticsSixth edOxford, UKAcademic Press2013124
  • WiseCAGarciaCADavisSNMolecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplicationAm J Hum Genet19935348538638105684
  • DiVincenzoCElzingaCDMedeirosACThe allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathyMol Genet Genomic Med20142652252925614874
  • BraathenGJGenetic epidemiology of Charcot-Marie-Tooth diseaseActa Neurol Scand Suppl2012193iv2223106488
  • BraathenGJSandJCLobatoAHoyerHRussellMBGenetic epidemiology of Charcot-Marie-Tooth in the general populationEur J Neurol2011181394820482598
  • BraathenGJSandJCLobatoAHøyerHRussellMBMFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT familiesBMC Med Genet2010114820350294
  • CasasnovasCBanchsICassereauJPhenotypic spectrum of MFN2 mutations in the Spanish populationJ Med Genet201047424925619889647
  • McCorquodaleDS3rdMontenegroGPegueroAMutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2J Neurol201125871234123921258814
  • BanchsICasasnovasCAlbertiADiagnosis of Charcot-Marie-Tooth diseaseJ Biomed Biotechnol2009200998541519826499
  • Rudnik-SchönebornSTölleDSenderekJDiagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patientsClin Genet Epub201548
  • FridmanVBundyBReillyMMCMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysisJ Neurol Neurosurg Psychiatry201586887387825430934
  • DrewAPZhuDKidambiAImproved inherited peripheral neuropathy genetic diagnosis by whole-exome sequencingMol Genet genomic Med20153214315425802885
  • ArnoldAMcEntagartMYoungerDSPsychosocial issues that face patients with Charcot-Marie-Tooth disease: The role of genetic counselingJ Genet Couns200514430731816047093
  • SiskindCEPanchalSSmithCOA review of genetic counseling for Charcot Marie Tooth disease (CMT)J Genet Couns201322442243623604902
  • YagermanSECrossMBGreenDWScherDMPediatric orthopedic conditions in Charcot-Marie-Tooth disease: a literature reviewCurr Opin Pediatr2012241505622189393
  • AbreschRTCarterGTHanJJMcDonaldCMExercise in neuromuscular diseasesPhys Med Rehabil Clin N Am201223365367322938880
  • AnensEEmtnerMHellstromKExploratory study of physical activity in persons with Charcot-Marie-Tooth diseaseArch Phys Med Rehabil201596226026825286435
  • McDonaldCMClinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseasesPhys Med Rehabil Clin N Am201223349556322938875
  • SkalskyAJMcDonaldCMPrevention and management of limb contractures in neuromuscular diseasesPhys Med Rehabil Clin N Am201223367568722938881
  • LawsonVHGordon SmithABrombergMBAssessment of axonal loss in Charcot-Marie-Tooth neuropathiesExp Neurol2003184275375714769367
  • van DijkJPVerhammeCvan SchaikINAge-related changes in motor unit number estimates in adult patients with Charcot-Marie-Tooth type 1AEur J Neurol20101781098110420443982
  • KrajewskiKMLewisRAFuerstDRNeurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1ABrain2000123Pt 71516152710869062
  • KrajewskiKTuranskyCLewisRCorrelation between weakness and axonal loss in patients with CMT1AAnn N Y Acad Sci199988349049210586281
  • YiuEMBurnsJRyanMMOuvrierRANeurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1AJ Peripher Nerv Syst200813323624118844790
  • VerhammeCvan SchaikINKoelmanJHde HaanRJde VisserMThe natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up studyBrain2009132Pt 123252326219843647
  • PaduaLPareysonDAprileINatural history of CMT1A including QoL: a 2-year prospective studyNeuromuscul Disord200818319920318242090
  • PaduaLPareysonDAprileINatural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of lifeNeurol Sci201031217517820016922
  • VinciPSerraoMMillulAQuality of life in patients with Charcot-Marie-Tooth diseaseNeurology200565692292416186535
  • ShyMERoseMRCharcot-Marie-Tooth disease impairs quality of life: why? And how do we improve it?Neurology200565679079116186514
  • PaduaLAprileICavallaroTRelationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter studyNeurol Sci200829315716218612763
  • RedmondACBurnsJOuvrierRAFactors that influence health-related quality of life in Australian adults with Charcot-Marie-Tooth diseaseNeuromuscul Disord200818861962518656353
  • ShyMEBlakeJKrajewskiKReliability and validity of the CMT neuropathy score as a measure of disabilityNeurology20056471209121415824348
  • MannilMSolariALehaASelected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patientsNeuromuscul Disord201424111003101725085517
  • BurnsJOuvrierREstilowTValidation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disabilityAnn Neurol201271564265222522479
  • VinciPPerplexity about the use of the Charcot-Marie-Tooth Neuropathy Score in rehabilitationEur J Phys Rehabil Med200844447347419002097
  • MurphySMHerrmannDNMcDermottMPReliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth diseaseJ Peripher Nerv Syst201116319119822003934
  • ReillyMMShyMEMuntoniFPareysonD168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT)Neuromuscul Disord2010201283984620850975
  • KomyathyKNealSFeelySAnterior tibialis CMAP amplitude correlations with impairment in CMT1AMuscle Nerve201347449349623456782
  • ChungKWKimSBParkKDEarly onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutationsBrain2006129Pt 82103211816835246
  • PareysonDReillyMRizzutoNCharcot-Marie-Tooth disease and ascorbic acid trials results of the CMT-TRIAAL and CMT-TRAUK. In: Twentieth Meeting of the European Neurological Society 19–23 June 2010 Berlin, GermanyJ Neurol2010257S104
  • FeelySMLauraMSiskindCEMFN2 mutations cause severe phenotypes in most patients with CMT2ANeurology201176201690169621508331
  • El-AbassiREnglandJDCarterGTCharcot-Marie-Tooth Disease: an overview of genotypes, phenotypes, and clinical management strategiesPM R20146434235524434692
  • BurnsJRamchandrenSRyanMMShyMOuvrierRADeterminants of reduced health-related quality of life in pediatric inherited neuropathiesNeurology201075872673120733147
  • RamchandrenSShyMFeldmanECarlosRSiskindCDefining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth diseaseJ Neurol Neurosurg Psychiatry201586663563925157034
  • JohnsonNEHeatwoleCRDilekNQuality-of-life in Charcot-Marie-Tooth disease: the patient’s perspectiveNeuromuscul Disord201424111018102325092060
  • AboussouanLSLewisRAShyMEDisorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth diseaseLung200718511717294338
  • BoentertMDziewasRHeidbrederAFatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based surveyJ Neurol2010257464665219937049
  • SouzaCCHirotsuCNevesELSleep pattern in Charcot-Marie-Tooth disease type 2: report of family case seriesJ Clin Sleep Med201511320521125515278
  • de Carvalho AlcântaraMNogueira-BarbosaMHFernandesRMRespiratory dysfunction in Charcot-Marie-Tooth disease type 1AJ Neurol201526251164117125761374
  • DematteisMPépinJLJeanmartMDeschauxCLabarre-VilaALévyPCharcot-Marie-Tooth disease and sleep apnoea syndrome: a family studyLancet2001357925226727211214130
  • DarquennesKDe JonghePDaemsDDe BackerWVerbraeckenJIntermittent positive airway pressure by nasal mask as a treatment for respiratory insufficiency in a patient with Charcot-Marie-Tooth diseaseActa Clin Belg200661417618117091914
  • BensonBSulicaLGussJBlitzerALaryngeal neuropathy of Charcot-Marie-Tooth disease: further observations and novel mutations associated with vocal fold paresisLaryngoscope2010120229129619950375
  • BoentertMKnopKSchuhmacherCGessBOkegwoAYoungPSleep disorders in Charcot-Marie-Tooth disease type 1J Neurol Neurosurg Psychiatry201485331932523704315
  • Rudnik-SchönebornSRöhrigDNicholsonGZerresKPregnancy and delivery in Charcot-Marie-Tooth disease type 1Neurology19934310201120168413959
  • HoffJMGilhusNEDaltveitAKPregnancies and deliveries in patients with Charcot-Marie-Tooth diseaseNeurology200564345946215699375
  • BrockMGuinnCJonesMAnesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: a case studyAANA J200977533533719911641
  • ChaudhryVChaudhryMCrawfordTOSimmons-O’BrienEGriffinJWToxic neuropathy in patients with pre-existing neuropathyNeurology200360233734012552058
  • HolzbaurELSchererSSMicrotubules, axonal transport, and neuropathyN Engl J Med2011365242330233222168648
  • WeimerLHPodwallDMedication-induced exacerbation of neuropathy in Charcot Marie Tooth diseaseJ Neurol Sci20062421–2475416386273
  • AttarianSVallatJMMagyLAn exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AOrphanet J Rare Dis2014919925519680
  • ChumakovIMiletACholetNPolytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathyOrphanet J Rare Dis2014920125491744
  • MandelJBertrandVLehertPA meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatmentOrphanet J Rare Dis2015107426070802
  • PassageENorreelJCNoack-FraissignesPAscorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth diseaseNat Med200410439640115034573
  • BurnsJOuvrierRAYiuEMAscorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trialLancet Neurol20098653754419427269
  • MicallefJAttarianSDubourgOEffect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trialLancet Neurol20098121103111019818690
  • VerhammeCde HaanRJVermeulenMBaasFde VisserMvan SchaikINOral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trialBMC Med200977019909499
  • PareysonDReillyMMSchenoneAAscorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trialLancet Neurol201110432032821393063
  • LewisRAMcDermottMPHerrmannDNHigh-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trialJAMA Neurol201370898198723797954
  • WilliamsLLO’DoughertyMMWrightFSBobulskiRJHorrocksLADietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth diseaseNeurology1986369120012053748386
  • RussellJWWindebankAJHarperCMJrTreatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridineMayo Clin Proc19957065325397776711
  • SeredaMWMeyer zu HörsteGSuterUUzmaNNaveKATherapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)Nat Med20039121533153714608378
  • Meyer zu HorsteGPrukopTLiebetanzDMobiusWNaveKASeredaMWAntiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathyAnn Neurol2007611617217262851
  • SahenkZNagarajaHNMcCrackenBSNT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patientsNeurology200565568168916157899
  • SahenkZGallowayGClarkKRAAV1.NT-3 gene therapy for charcot-marie-tooth neuropathyMol Ther201422351152124162799
  • KuhlenbaumerGYoungPHunermundGRingelsteinBStogbauerFClinical features and molecular genetics of hereditary peripheral neuropathiesJ Neurol2002249121629165012529785
  • VinciPGait rehabilitation in a patient affected with Charcot-Marie-Tooth disease associated with pyramidal and cerebellar features and blindnessArch Phys Med Rehabil200384576276512736893
  • SackleyCDislerPBTurner-StokesLWadeDTBrittleNHoppittTRehabilitation interventions for foot drop in neuromuscular diseaseCochrane Database Syst Rev20093CD00390819588347
  • SmanADRaymondJRefshaugeKMRandomised controlled trial protocol of foot and ankle exercise for children with Charcot-Marie-Tooth diseaseJ Physiother201460155 discussion 5524856942
  • LencioniTRabuffettiMPiscosquitoGPostural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjectsGait Posture201440448148625082324
  • VinciPEspositoCPerelliSLAntenorJAThomasFPOverwork weakness in Charcot-Marie-Tooth diseaseArch Phys Med Rehabil200384682582712808533
  • PiscosquitoGReillyMMSchenoneAIs overwork weakness relevant in Charcot-Marie-Tooth disease?J Neurol Neurosurg Psychiatry201485121354135824659795
  • RoseKJBurnsJWheelerDMNorthKNInterventions for increasing ankle range of motion in patients with neuromuscular diseaseCochrane Database Syst Rev20102CD00697320166090
  • BurnsJBrayPCrossLANorthKNRyanMMOuvrierRAHand involvement in children with Charcot-Marie-Tooth disease type 1ANeuromuscul Disord2008181297097318993073
  • DufekJSNeumannESHawkinsMCO’TooleBFunctional and dynamic response characteristics of a custom composite ankle foot orthosis for Charcot-Marie-Tooth patientsGait Posture201439130831323958459
  • GuillebastreBCalmelsPRougierPRAssessment of appropriate ankle-foot orthoses models for patients with Charcot-Marie-Tooth diseaseAm J Phys Med Rehabil201190861962721681059
  • RamdharryGMDayBLReillyMMMarsdenJFFoot drop splints improve proximal as well as distal leg control during gait in Charcot-Marie-Tooth diseaseMuscle Nerve201246451251922987691
  • MenottiFLaudaniLDamianiAMignognaTMacalusoAAn anterior ankle-foot orthosis improves walking economy in Charcot-Marie-Tooth type 1A patientsProsthet Orthot Int201438538739224100074
  • ScheffersGHillerCRefshaugeKBurnsJPrescription of foot and ankle orthoses for children with Charcot-Marie-Tooth disease: a review of the evidencePhys Ther Rev20121727990
  • WegenerCBurnsJPenkalaSEffect of neutral-cushioned running shoes on plantar pressure loading and comfort in athletes with cavus feet: a crossover randomized controlled trialAm J Sports Med200836112139214618577583
  • VinciPGargiuloPPoor compliance with ankle-foot-orthoses in Charcot-Marie-Tooth diseaseEur J Phys Rehabil Med2008441273118385625
  • PhillipsMFRobertsonZKillenBWhiteBA pilot study of a crossover trial with randomized use of ankle-foot orthoses for people with Charcot-Marie-tooth diseaseClin Rehabil201226653454422089961
  • FaldiniCTrainaFNanniMSurgical treatment of cavus foot in Charcot-Marie-tooth disease: a review of twenty-four cases: AAOS exhibit selectionJ Bone Joint Surg Am2015976e3025788311
  • BoffeliTJTabattJAMinimally Invasive Early Operative Treatment of Progressive Foot and Ankle Deformity Associated With Charcot-Marie-Tooth DiseaseJ Foot Ankle Surg201554470170825131389
  • BurnsJRaymondJOuvrierRFeasibility of foot and ankle strength training in childhood Charcot-Marie-Tooth diseaseNeuromuscul Disord2009191281882119819697
  • El MhandiLMilletGYCalmelsPBenefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth diseaseMuscl Nerve2008375601610
  • ChetlinRDGutmannLTarnopolskyMUllrichIHYeaterRAResistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescriptionArch Phys Med Rehabil20048581217122315295743
  • SaportaASDSottileSLMillerLJFeelySMESiskindCEShyMECharcot-Marie-Tooth disease subtypes and genetic testing strategiesAnn Neurol2011691223321280073
  • MillerLJSaportaASDSottileSLSiskindCEFeelySMEShyMEStrategy for genetic testing in Charcot-Marie-diseaseActa Myol201130210911622106713